A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance
Monitoring allows early intervention if rapid regain occurs, and your provider can discuss restarting therapy, switching to a compounded tirzepatide product through PlexusDx, or exploring combination strategies such as the GLP-Squared dual-compound injection (semaglutide + tirzepatide) at $289/mo month-to-month, or from $249/mo on the 6-month plan
One study found weight discrimination was linked to a 60% higher risk of dying early comparable to smoking
As a step therapy medication Contrave is a common step therapy requirement before insurance plans will approve GLP-1 medications like Wegovy or Zepbound
If there is no response, raise to the maximum dose for another two to four weeks
These studies include examination of cardiovascular outcomes, essential for demonstrating safety in the target population and securing favorable insurance coverage decisions